Converting to Eylea from Avastin may benefit Patients with Diabetic Macular Edema

(c) British Journal of Ophthalmology

A study from Portugal, published in Graefe's Archive for Clinical and Experimental Ophthalmology, finds changing from bevacizumab (avastin) to aflibercept (eylea) for persistent diabetic macular edema resulted in functional and anatomical improvements. Central macular thickness previous to starting aflibercept was found to be a predictor of anatomical changes after aflibercept.